Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

May 22, 2024

Company Anicom Holdings, Inc.
Representative Director Nobuaki Komori
(Securities Code: 8715 TSE PRIME)
Inquiries to Norihiko Sakurai
Corporate Planning Department,
General Manager

Monthly Management Parameters, April 2024

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Monthly Management Parameters, FY2024 (From April 1, 2024 to March 31, 2025)

	April	May	June	July	August	September
Net premiums written (previous year)	**4,670**JPYmn (4,346 JPYmn)	JPYmn (4,594 JPYmn)	JPYmn (4,386 JPYmn)	JPYmn (4,367 JPYmn)	JPYmn (4,486 JPYmn)	JPYmn (4,515 JPYmn)
No. of policies in force (previous year)	**1,199,358** (1,119,862)	(1,126,210)	(1,132,856)	(1,140,258)	(1,147,355)	(1,154,322)
Renewal rate (previous year)	**88.2**% (88.3%)	% (87.8%)	% (88.3%)	% (88.3%)	% (88.1%)	% (88.2%)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	**18,886** (18,514)	(18,945)	(17,822)	(16,835)	(17,833)	(18,258)
No. of PARM hospitals[*1] (previous year)	**736** (647)	(654)	(661)	(667)	(675)	(683)
No. of patents held[*2] (previous year)	**18** (11)	(11)	(11)	(11)	(13)	(13)

	October	November	December	January	February	March
Net premiums written (previous year)	JPYmn (4,544 JPYmn)	JPYmn (4,465 JPYmn)	JPYmn (4,564 JPYmn)	JPYmn (4,738 JPYmn)	JPYmn (4,533 JPYmn)	JPYmn (4,731 JPYmn)
No. of policies in force (previous year)	(1,160,624)	(1,166,524)	(1,172,819)	(1,180,363)	(1,186,940)	(1,193,560)
Renewal rate (previous year)	% (88.1%)	% (88.4%)	% (88.4%)	% (88.2%)	% (88.4%)	% (88.4%)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	(19,039)	(17,722)	(18,017)	(18,648)	(18,394)	(20,386)
No. of PARM hospitals*1 (previous year)	(692)	(693)	(699)	(703)	(711)	(729)
No. of patents held*2 (previous year)	(15)	(15)	(15)	(17)	(18)	(18)

*1 This is a key figure regarding the progress of the regenerative medicine business.
The "Research and Development Partnership for Animal Regenerative Medicine (PARM)" is a non-profit mutual benefit corporation. Its purpose is to take advantage of industry-government-academia collaboration in order to standardize each process of cell therapy services for domestic animals (dogs and cats) and achieve the practical application of a system that makes it possible for veterinarians at all kinds of medical facilities to provide safe and effective cell therapy services.

*2 We disclose the figure as a key figure related to the promotion of BioInsurTech using big data, with the aim of realizing a prevention-oriented company that prevents injuries and illnesses before they occur.

(Reference) “Monthly Management Parameters” will be disclosed after middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December, and March.